Methods and products for transfecting cells
First Claim
1. A method for treating HIV infection in a human subject, comprising:
- (a) harvesting a hematopoietic cell from the subject;
(b) gene-editing the hematopoietic cell by transfecting the hematopoietic cell with an in vitro transcribed synthetic RNA molecule encoding a gene-editing protein, whereinthe hematopoietic cell expresses the gene-editing protein, andthe gene-editing protein comprises a DNA-binding domain and a nuclease catalytic domain that causes a double-strand break in the DNA of the hematopoietic cell to reduce the function of a gene selected from CCR5 and CXCR4; and
(c) administering the gene-edited hematopoietic cell to the subject to result in the treatment of HIV infection in the subject.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
-
Citations
9 Claims
-
1. A method for treating HIV infection in a human subject, comprising:
-
(a) harvesting a hematopoietic cell from the subject; (b) gene-editing the hematopoietic cell by transfecting the hematopoietic cell with an in vitro transcribed synthetic RNA molecule encoding a gene-editing protein, wherein the hematopoietic cell expresses the gene-editing protein, and the gene-editing protein comprises a DNA-binding domain and a nuclease catalytic domain that causes a double-strand break in the DNA of the hematopoietic cell to reduce the function of a gene selected from CCR5 and CXCR4; and (c) administering the gene-edited hematopoietic cell to the subject to result in the treatment of HIV infection in the subject. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
Specification